Phacilitate Leaders World

Investment for Advanced Therapies

Investors joined us as VIP guests and met some of the world's most exciting companies within advanced therapeutics (cell, gene and immuno-oncology)

Over the past 14 years Phacilitate has built up a full eco-system event consisting of the world’s most exciting emerging biotech companies within cell, gene and immuno-therapies.

We have seen a dramatic increase in the number of biotech’s looking to secure investment at our conferences. As such our goal is to connect the investment community with our biotech audience in order to advance innovation in advanced therapies.

This past January Phacilitate was proud to host the world’s largest advanced therapy partnering conference. With investors playing a key role in the commercialisation of these therapies, we were able to build out our investment community at the event.  

Why Investors attended

  1. Phacilitate is the world’s largest business partnering event purely dedicated to Advanced Therapies. With 1,400 delegates you will benefit from meeting the most active and promising Cell, Gene and I-O companies and their management teams all under one roof. All stages are represented from early academic spinouts and emerging biotech through to growth stage and public.
     
  2. Phacilitate’s conference programme provides the world’s most comprehensive overview of the challenges and opportunities in cell, gene and immunotherapy.  This allows investors to get ahead of the curve, understand current pipelines and spot the best opportunities on the horizon. The event also attracts seasoned investors with experience in the field who are searching for partners as well as analysts who can provide direction and guidance.
     
  3. Phacilitate offers the industry’s best partnering tool and meeting service to easily connect you with companies and individuals of interest. In addition to this we offer a wide selection of informal partnering events to help expand your network including cocktail receptions and a Yacht Party!

 

 

What kind of biotechs do you typically invest in?

Sourcing the best investment and learning opportunities can be difficult; we’ve split the agenda into phases to make your life easier. Click to view the different emerging biotech:

Cell and Gene Therapy World Logo Immuno Oncology Frontiers World

 

The Power of Partnerships

Phacilitate believes in the power of partnerships, which is why the Phacilitate Leaders Forum is the foremost partnering and networking event in the industry’s calendar. There is a plethora of ways to network:

Exhibition Drinks 

Exhibition Drinks 

Network with attendees after the close of Day 1 with a drinks reception in the Exhibition area 
Gala Drinks

Gala Drinks

Join the Gala welcome drinks on the Terrace and connect with industry leaders
Personalized Event Planner

Personalized Event Planner

Welcome to your personalized event planner, private social network and partnering tool 

Academia in attendance

World-renowned speakers

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK